Publication

Article

CURE

Summer 2007
Volume6
Issue 4

Noting Group Differences

Despite the gains noted in the overall number of Medicare patients undergoing colonoscopy, researchers continue to see differences in colorectal cancer screening rates among certain groups, particularly minorities.

Despite the gains noted in the overall number of Medicare patients undergoing colonoscopy, researchers continue to see differences in colorectal cancer screening rates among certain groups, particularly minorities.

One recent study, of almost 600,000 people covered by Medicare in three states, found that as a group, people of color were only about half as likely as whites to be screened for colorectal cancer. In addition, women were more likely than men to undergo some type of screening but less likely than men to have a colonoscopy.

The study, published in February in the Archives of Internal Medicine, also found that populations with higher income levels were more likely to undergo a colon screening test than those that were poorer. Yet even after adjusting for the income difference, the scientists, from the Medical College of Wisconsin in Milwaukee, still found that nonwhites had lower screening rates.

That finding, wrote the researchers, “is worrisome because both colon cancer incidence and mortality are higher than in whites.”

Related Videos
Image of Dr. Fakih.
Image of Doctor with blonde hair.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Scott Kopetz
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Related Content